Publications of Ashok Kumar Jayavelu

Vorwerk, J.; Sun, K.; Frank, D.; Neumann, F.; Hueve, J.; Budde, P. M.; Liu, L.; Xie, X.; Patnana, P. K.; Ahmed, H. M. M. et al.; Opalka, B.; Lenz, G.; Jayavelu, A. K.; Khandanpour, C.: Presence of the GFI1-36N single nucleotide polymorphism enhances the response of MLL-AF9 leukemic cells to CDK4/6 inhibition. Frontiers in Oncology 12, 903691 (2022)

Zeller, C.; Richter, D.; Jurinovic, V.; Valtierra-Gutierrez, I. A.; Jayavelu, A. K.; Mann, M.; Bagnoli, J. W.; Hellmann, I.; Herold, T.; Enard, W. et al.; Vick, B.; Jeremias, I.: Adverse stem cell clones within a single patient's tumor predict clinical outcome in AML patients. Journal of Hematology & Oncology 15, 25 (2022)

Schnoeder, T. M.; Schwarzer, A.; Jayavelu, A. K.; Hsu, C. J.; Kirkpatrick, J.; Dohner, K.; Perner, F.; Eifert, T.; Huber, N.; Arreba-Tutusaus, P. et al.; Dolnik, A.; Assi, S. A.; Nafria, M.; Jiang, L.; Dai, Y. T.; Chen, Z.; Chen, S. J.; Kellaway, S. G.; Ptasinska, A.; Ng, E. S.; Stanley, E. G.; Elefanty, A. G.; Buschbeck, M.; Bierhoff, H.; Brodt, S.; Matziolis, G.; Fischer, K. D.; Hochhaus, A.; Chen, C. W.; Heidenreich, O.; Mann, M.; Lane, S. W.; Bullinger, L.; Ori, A.; von Eyss, B.; Bonifer, C.; Heidel, F. H.: PLCG1 is required for AML1-ETO leukemia stem cell self-renewal. Blood 139 (7), pp. 1080 - 1097 (2022)

Perner, F.; Schnoeder, T. M.; Xiong, Y. J.; Jayavelu, A. K.; Mashamba, N.; Santamaria, N. T.; Huber, N.; Todorova, K.; Hatton, C.; Perner, B. et al.; Eifert, T.; Murphy, C.; Hartmann, M.; Hoell, J. I.; Schroder, N.; Brandt, S.; Hochhaus, A.; Mertens, P. R.; Mann, M.; Armstrong, S. A.; Mandinova, A.; Heidel, F. H.: YBX1 mediates translation of oncogenic transcripts to control cell competition in AML. Leukemia 36 (2), pp. 426 - 437 (2022)

Jayavelu, A. K.; Wolf, S.; Buettner, F.; Alexe, G.; Haeupl, B.; Comoglio, F.; Schneider, C.; Doebele, C.; Fuhrmann, D. C.; Wagner, S. et al.; Donato, E.; Andresen, C.; Wilke, A. C.; Zindel, A.; Jahn, D.; Splettstoesser, B.; Plessmann, U.; Muench, S.; Abou-El-Ardat, K.; Makowka, P.; Acker, F.; Enssle, J. C.; Cremer, A.; Schnutgen, F.; Kurrle, N.; Chapuy, B.; Loeber, J.; Hartmann, S.; Wild, P. J.; Wittig, I.; Huebschmann, D.; Kaderali, L.; Cox, J.; Bruene, B.; Roellig, C.; Thiede, C.; Steffen, B.; Bornhaeuser, M.; Trumpp, A.; Urlaub, H.; Stegmaier, K.; Serve, H.; Mann, M.; Oellerich, T.: The proteogenomic subtypes of acute myeloid leukemia. Cancer Cell 40 (3), pp. 301 - 317.e12 (2022)

Haider, N.; Lebastchi, J.; Jayavelu, A. K.; Batista, T. M.; Pan, H.; Dreyfuss, J. M.; Carcamo-Orive, I.; Knowles, J. W.; Mann, M.; Kahn, C. R.: Signaling defects associated with insulin resistance in nondiabetic and diabetic individuals and modification by sex. Journal of Clinical Investigation 131 (21), e151818 (2021)

Batista, T. M.; Jayavelu, A. K.; Wewer Albrechtsen, N. J.; Iovino, S.; Lebastchi, J.; Pan, H.; Dreyfuss, J. M.; Krook, A.; Zierath, J. R.; Mann, M. et al.; Kahn, C. R.: A Cell-Autonomous Signature of Dysregulated Protein Phosphorylation Underlies Muscle Insulin Resistance in Type 2 Diabetes. Cell Metabolism 32 (5), pp. 844 - 859.e5 (2020)

Jayavelu, A. K.; Schnöder, T.M.; Perner, F.; Herzog, C.; Meiler, A.; Krishnamoorthy, G.; Huber, N.; Mohr, J.; Edelmann-Stephan, B.; Austin, R. et al.; Brandt, S.; Palandri, F.; Schröder, N.; Isermann, B.; Edlich, F.; Sinha, A.U.; Ungelenk, M.; Hübner, C.A.; Zeiser, R.; Rahmig, S.; Waskow, C.; Coldham, I.; Ernst, T.; Hochhaus, A.; Jilg, S.; Jost, P.J.; Mullally, A.; Bullinger, L.; Mertens, P.R.; Lane, S.W.; Mann, M.; Heidel, F.H.: Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms. Nature 588, pp. 157 - 163 (2020)

Reich, D.; Kresinsky, A.; Müller, J. P.; Bauer, R.; Kallenbach, J.; Schnoeder, T. M.; Heidel, F. H.; Fässler, R.; Mann, M.; Böhmer, F.-D. et al.; Jayavelu, A. K.: SHP1 regulates a STAT6-ITGB3 axis in FLT3ITD-positive AML cells. LEUKEMIA 34 (5), pp. 1444 - 1449 (2020)

Moloney, J. N.; Jayavelu, A. K.; Stanicka, J.; Roche, S. L.; O'Brien, R. L.; Scholl, S.; Boehmer, F.-D.; Cotter, T. G.: Nuclear membrane-localised NOX4D generates pro-survival ROS in FLT3-ITD-expressing AML. Oncotarget 8 (62), pp. 105440 - 105457 (2017)

Tsitsipatis, D.; Jayavelu, A. K.; Mueller, J. P.; Bauer, R.; Schmidt-Arras, D.; Mahboobi, S.; Schnoeder, T. M.; Heidel, F.; Boehmer, F.-D.: Synergistic killing of FLT3ITD-positive AML cells by combined inhibition of tyrosine-kinase activity and N-glycosylation. Oncotarget 8 (16), pp. 26613 - 26624 (2017)

Schmid, J. P.; Bahrami, E.; Becker, M.; Jayavelu, A. K.; Wirth, A. K.; Jurinovic, V.; Oellinger, R.; Vick, B.; Herold, T.; Jeremias, I.: ADAM10's sheddase function augments the interaction of leukemia cells with the bone marrow niche in PDX models in vivo. In KLINISCHE PADIATRIE, 234 (03), p. 183 - 183. GEORG THIEME VERLAG KG, RUDIGERSTR 14, D-70469 STUTTGART, GERMANY (2022)

Frank, D.; Jayavelu, A. K.; Wei, L.; Al-Matary, Y.; Patnana, P. K.; Nimmagadda, S. C.; Heuser, M.; Thol, F.; Goehring, G.; Thomale, J. et al.; Pfaus, A.; Rad, R.; Jeremias, I.; Vick, B.; Hoffmann, S.; Stoelzel, F.; Dill, C.; Altmann, H.; Kunadt, D.; Schliemann, C.; Mikesch, J. -.; Arteaga-Paz, M. F.; Berdel, W.; Khandanpour, C.: A single nucleotide polymorphism of the transcription factor Growth Factor Independence 1 (GFI1) accelerates AML evolution and sensitizes AML cells to treatment with DNA repair inhibitors. In Oncology Research and Treatment, 43 (SUPPL 4), pp. 36 - 37. Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020: Abstracts, October 09, 2020 - October 11, 2020. Karger, Basel (2020)